NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Pharma POOL Jean-Louis Anspach Michael R. Dornhecker Ann Willmoth Solvay Pharmaceuticals Announces Key Promotions Solvay Pharmaceuticals, Marietta, Ga., has named Jean-Louis Anspach as VP, commercial operations, responsible for managing all aspects of the primary-care business unit, including sales and marketing activities for its specialized markets and cardiology portfolios. Solvay Pharmaceuticals is a research-driven pharmaceutical company that seeks to fulfill unmet medical needs in the therapeutic areas of cardiology, gastroenterology, mental health, women’s health, and a select group of specialized markets, including men’s health. A veteran of the Solvay S.A. group of companies, of which Solvay Pharmaceuticals is a subsidiary, Mr. Anspach has been with the company since 1999 and most recently served as VP of marketing. Mr. Anspach holds an ingenieur commercial degree from Universite Libre de Bruxelles, Belgium. He also has a MBA from the University of Wisconsin — Madison. Solvay also has appointed Michael R. Dornhecker to VP of manufacturing and operations. He oversees all aspects of product manufacturing, warehousing, and distribution; site safety protocols; and overall facility administration at the company’s Baudette, Minn., production facilities and its Marietta corporate offices. Mr. Dornhecker has spent 13 years in manufacturing at Solvay Pharmaceticals, most recently as general manager of operations at the Baudette manufacturing facility. He holds a bachelor’s degree in supervision technology from Purdue University. Ann Willmoth has been promoted to VP, commercial development and services, responsible for healthcare solutions marketing and managed markets; trade affairs and pharmacy development; commercial and corporate training and development; sales operations and salesforce effectiveness; and U.S. portfolio development. Ms. Willmoth, who joined Solvay in 1997, previously served as VP of sales. An active member of the Healthcare Businesswomen’s Association, Ms. Willmoth holds a bachelor’s degree in education from the University of Kentucky and a master’s degree in education from Georgia State University. Dr. Susan G. Arbuck Christopher Kelly Dr. James F. McLeod Schering-Plough Announces Staff Additions Schering-Plough, Kenilworth, N.J., a global science-based healthcare company, has announced three key executive appointments. Susan G. Arbuck, M.D., has been appointed VP of oncology, global clinical development, for Schering-Plough Research Institute. She is responsible for the global clinical development of oncology products and represents the global clinical development group on an internal product development committee. Dr. Arbuck comes to Schering-Plough from Aventis Pharmaceuticals, where she served as VP and global head of the oncology therapeutic area. A board-certified medical oncologist, she has published more than 100 peer-reviewed publications and has participated for 10 years in the FDA’s National Cancer Institute working group meetings. She holds a B.Sc. from the University of Toronto, a M.Sc. in pharmacology from the State University of New York at Buffalo, and a M.D. from McMaster University Medical School. Christopher Kelly has joined Schering-Plough as VP, global information technology, global supply chain/global quality operations. He provides strategic IT leadership for supply chain and quality systems initiatives worldwide. Most recently, he served as partner, business consulting services, at IBM, where he led the U.S. pharmaceutical industry technology strategy and management practice. Mr. Kelly holds a diploma in management studies from Staffordshire Polytechnic and a MBA from Staffordshire University Business School. Additionally, James F. McLeod, M.D., has been named VP, global clinical development, early clinical research and experimental medicine for Schering-Plough Research Institute. He oversees early clinical research (clinical pharmacology) activities across early development projects; chairs the committee responsible for decisions on initial clinical trials of experimental medicines; and serves as a member of the early development committee. He also provides clinical guidance in the linkage of preclinical models and early clinical experience. Dr. McLeod previously was with Novartis Pharmaceuticals, where he held VP positions in translational medicine and clinical pharmacology, clinical development, and medical affairs. He holds a B.S. from Rensselaer Polytechnic Institute and a M.D. from the University of Connecticut. Peter Arduini Baxter Announces Key Executive Appointment Baxter International, Deerfield, Ill., a healthcare company with expertise in medical devices, pharmaceuticals, and biotechnology, has named two senior executives to key leadership roles. Peter J. Arduini has been named corporate VP and president of Baxter’s medication delivery business, replacing David F. Drohan, who has retired after 39 years with the company. Mr. Arduini, 41, comes to Baxter after spending 15 years at General Electric Healthcare. Most recently, he was global general manager of its CT scan and functional imaging business. Mr. Arduini earned his MBA from Northwestern University’s Kellogg Graduate School of Management, after graduating from Susquehanna University with a B.S. in marketing. Kim Stratton Novartis Pharma Names Head of Respiratory and Dermatology Franchise Novartis Pharmaceuticals, East Hanover, N.J., has appointed Kim Stratton as VP of respiratory and dermatology. She is responsible for leading the U.S. business for these franchises. Novartis Pharmaceuticals, an affiliate of Novartis AG based in Basel, Switzerland, researches, develops, manufacturers, and markets prescription drugs for a wide range of a diseases and conditions. Ms. Stratton, who has been with Novartis since 1998, most recently served as global head, respiratory and dermatology, for Novartis Pharma AG. Biotech POOL Dr. Richard Fisher GlycoFi Names VP, Research and Product Development Richard Fisher, Ph.D. has been named VP of research and product development at GlycoFi, Lebanon, N.H., a biotechnology company that leverages its pioneering protein production technology to develop, produce, and commercialize next-generation biotherapeutics. Dr. Fisher is responsible for leading and managing the company’s research and product development functions. He brings 24 years of research experience in the pharmaceutical industry, most recently as VP of research and discovery at UCB Research, the research and discovery subsidiary of UCB Pharma. Dr. Fisher replaces Tillman Gerngross, Ph.D., who remains GlycoFi’s chief scientific officer and a member of its board of directors. Dr. Christopher Henney Xcyte Therapies Appoints Chairman Xcyte Therapies has appointed Christopher Henney, Ph.D., a 20-year veteran of the biotech industry, as chairman of the board of directors. Seattle-based Xcyte is a biotechnology company developing therapeutic products designed to enhance the body’s natural immune responses. Dr. Henney most recently served as chairman, CEO, and director of Dendreon. Previously, he cofounded ICOS and Immunex. He received a D.Sc. for his contributions to immunology, a Ph.D. in experimental pathology, and a B.Sc., with honors, from the University of Birmingham, England. Paul Hopper Advanced Biotherapy Appoints Director of Business Development Paul Hopper has been named director of business development at Advanced Biotherapy, a Los Angeles-based biotechnology company that develops therapeutic antibodies to treat autoimmune diseases. Mr. Hopper is responsible for pursuing licensing opportunities and targeting prospective acquisition and merger candidates. Formerly CEO of Australian Cancer Technology, Mr. Hopper has more than 25 years experience in the healthcare industry. William N. Plamondon III Protein Polymer Technologies Selects CEO Protein Polymer Technologies (PPTI), San Diego, has appointed William N. Plamondon III to the position of CEO. PPTI develops products to improve medical and surgical outcomes. For the past seven months, Mr. Plamondon has been an advisor to PPTI. He also is a member of the board of directors. He most recently served as president and CEO of R.I. Heller, a management consulting firm. J. Thomas Parmeter, PPTI’s former CEO, has remained in his capacity as chairman of the board of directors. Biopharmaceutical POOL Dr. Samuel L. Barker Dr. C. Thomas Caskey Lexicon Announces Changes in Board Leadership Lexicon Genetics, The Woodlands, Texas, has appointed Samuel L. Barker, Ph.D., as chairman of the board of directors. Dr. Barker has been a director of the biopharmaceutical company since March 2000. From July 2003 until November 2004, he served as president and CEO of Clearview Projects, a company that he cofounded in 2001. Dr. Barker has assumed the role of chairman from C. Thomas Caskey, M.D., who held the post for five years and continues to serve on the board as a director. Dr. Caskey also serves as a consultant on government affairs, responsible for furthering the company’s relationships with regional and national government agencies to expand its opportunities to compete for funding related to human disease, biodefense, and other government-sponsored research initiatives. Before his term as Lexicon’s chairman, Dr. Caskey served as senior VP, research at Merck Research Laboratories. Dr. M. Timothy Cooke AVANT Creates Chief Operating Officer Position AVANT Immunotherapeutics has promoted M. Timothy Cooke, Ph.D. to the newly created position of chief operating officer. The biopharmaceutical company, located in Needham, Mass., uses novel applications of immunology to discover, develop, and sell vaccines and therapeutics that harness the human immune system to prevent and treat disease. Formerly senior VP of commercial development, Dr. Cooke has assumed responsibility for research and product development, manufacturing, and business development functions. He continues to oversee project management and strategic marketing activities. Before joining AVANT, Dr. Cooke was CEO of Mojave Therapeutics. He holds a B.S. from Saint Joseph’s University and a MBA from the Columbia Business School. He earned his Ph.D. in bio-organic chemistry from Columbia University. Dr. Adam R. Craig Dr. Eric E. Poma Innovive Names VPs Adam R. Craig, M.D., Ph.D., has joined Innovive Pharmaceuticals, a New York-based biopharmaceutical company, as VP and chief medical officer. Innovive acquires, develops, and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. Most recently, Dr. Craig was with ArQule, where he served as medical director and VP, clinical development, and was a member of the company’s executive team. The author of numerous journal articles and abstracts on oncology, Dr. Craig earned bachelor of medicine and bachelor of surgery degrees from Charing Cross and Westminster Medical School, University of London. He holds a Ph.D. in molecular medicine from the University of Leeds and a MBA from the Open University Business School. Eric E. Poma, Ph.D., has been named VP, business development at Innovive. Dr. Poma joins Innovive from ImClone Systems, where he was assistant VP of business development, responsible for all licensing and partnership agreements. He holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill, School of Medicine. He also holds a MBA from the Leonard N. Stern School of Business at New York University and a B.S. in biology from the University of North Carolina at Chapel Hill. Dr. Peter Letendre Replidyne Selects Chief Commercial Officer Peter Letendre, Pharm.D., has been appointed chief commercial officer of Replidyne, Louisville, Colo., a biopharmaceutical company focused on discovering and developing novel anti-infective drugs. Dr. Letendre joins Replidyne from Abbott, where he was the divisional VP and general manager of the anti-infective franchise. He attended the Massachusetts College of Pharmacy and Allied Health Sciences, where he earned B.S. and Pharm.D. degrees. G. John Mohr Topigen Hires Chief Business Officer Topigen Pharmaceuticals, Montreal, a biopharmaceutical company developing anti-inflammatory respiratory products, has appointed G. John Mohr as chief business officer, responsible for all business and corporate development functions, including strategic collaborations, acquisitions, and marketing. Mr. Mohr, a certified public accountant, previously was responsible for licensing and corporate development functions at Atherogenics and Fournier Pharma. Eric Pauwels TKT Appoints Senior VP, Global Commercial Operations Eric Pauwels has been named senior VP of global commercial operations at Transkaryotic Therapies (TKT), Cambridge, Mass., a biopharmaceutical company focused on researching, developing, and commercializing treatments for rare diseases caused by protein deficiencies. Mr. Pauwels has overall responsibility for worldwide commercialization initiatives, including TKT’s anticipated first commercial U.S. launch in 2006. Additionally, he provides commercial input on the prioritization and value of TKT’s emerging new product pipeline. Mr. Pauwels brings to TKT more than 20 years of commercial pharmaceutical experience, most recently as VP of global strategic marketing, men’s health, at Bayer HealthCare Pharmaceuticals, where he managed the global commercialization for Levitra. He holds a B.Sc. from California State Polytechnic University. Specialty POOL Grant D. Carlson Nanobac Names President and Chief Operating Officer Nanobac Life Sciences has promoted Grant D. Carlson to president and chief operating officer from VP of business development. He is responsible for the day-to-day operations of Nanobac’s in vitro diagnostics, dietary supplement, and drug-discovery businesses. Nanobac, based in Tampa, Fla., is dedicated to improving people’s health through the detection and eradication of nanobacteria. Before joining Nanobac, Mr. Carlson was VP of marketing and business development at Agilix. He is co-inventor on five U.S. patents and author of several scientific papers in the areas of oncology, urology, and diagnostic pathology. He holds a B.S. in kinesiology from the University of California, Los Angeles. Dianne Denton Chris Foy SkinMedica Expands Executive Team SkinMedica, Carlsbad, Calif., has promoted Dianne Denton to VP of pharmaceutical marketing, and Chris Foy to VP of pharmaceutical sales. The two executives are responsible for marketing and sales of the specialty pharmaceutical company’s two products, Vaniqa and EpiQuin Micro, to the U.S. dermatology market. Ms. Denton joined SkinMedica in 2003 after having held management and director-level positions at Abbott and Siemens. She earned a B.S. from Northern Illinois University and a MBA in finance and marketing from the University of Chicago’s Graduate School of Business. Mr. Foy, who also joined SkinMedica in 2003, previously spent 23 years with GlaxoSmithKline, where he most recently served as VP of sales. He holds a B.S. in business administration from Northeastern Oklahoma State University. Dr. Milind S. Deshpande Kevin L. Eastwood Achillion Announces Executive Promotions Achillion Pharmaceuticals, New Haven, Conn., a pharmaceutical company focused on the discovery and development of small-molecule drugs for the treatment of HIV, hepatitis, and resistant bacterial infections, has announced two management promotions. Milind S. Deshpande, Ph.D., has been named chief scientific officer and senior VP of research. Dr. Deshpande joined Achillion as VP of chemistry in September 2001 and was promoted to head of drug discovery in April 2002 and VP of drug discovery in December 2002. Before joining Achillion, Dr. Deshpande was associate director in chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb. Following his education in India, Dr. Deshpande received his Ph.D. in organic chemistry from Ohio University. Kevin L. Eastwood has been named senior VP of business development. Since joining Achillion in June 2000, Mr. Eastwood has led the company’s business development efforts, having executed both license and cooperative research agreements as well as a series of strategic collaborative discovery agreements. Previously, he served as manager of business development at Agouron-Pfizer Pharmaceuticals. He holds a B.S. in biology from Southwest Missouri State University. David Fink Dr. James Lynch Savient Strengthens Senior Management Team Savient Pharmaceuticals, East Brunswick, N.J., a specialty pharmaceutical company engaged in developing, manufacturing, and marketing pharmaceuticals to address unmet medical needs in both niche and broader markets, has expanded its management team with two key executive-level appointments. David Fink, a 20-year veteran of the pharma industry, has been named senior VP of commercial operations, responsible for all U.S. sales and marketing activities in support of Savient’s current brands, Oxandrin and Delatestryl. Additionally, he is overseeing the creation and deployment of a new salesforce to support the recently announced copromotion agreement with Ferring Pharmaceuticals to market Nuflexxa. Mr. Fink comes to Savient from MedPointe Pharmaceuticals, where he was VP of marketing. He holds a MBA from the University of Wisconsin at Milwaukee and a B.S. in business from Radford University. Additionally, James Lynch, Ph.D., has been appointed VP of business development, responsible for global business development activities, focusing on the execution of Savient’s initiative to actively in-license or acquire novel compounds in clinical development as well as marketed compounds complementary to the company’s strategic direction. Most recently, Dr. Lynch was an original member of Reliant Pharmaceuticals’ management team and leader of business development initiatives. He earned his MBA from Columbia University, his Ph.D. in inorganic chemistry from Seton Hall University, and his B.S. in chemistry from Siena College. Keith D. Ignotz DiaKine Therapeutics Names President and CEO DiaKine Therapeutics, a diabetes pharmaceutical company based in Charlottesville, Va., has announced the appointment of Keith D. Ignotz to the position of president and CEO. Mr. Ignotz, who has more than 20 years of healthcare experience, previously served as president and chief operating officer of SpectRx, which he cofounded. He holds a MBA from Pepperdine University. Dr. Philip Jochelson Somaxon Pharmaceuticals Appoints Senior VP and Chief Medical Officer Philip Jochelson, M.D., has been named senior VP and chief medical officer at Somaxon Pharmaceuticals, San Diego, a specialty pharmaceutical company developing products for the treatment of neuropsychiatric disorders. Dr. Jochelson is responsible for leading all phases of clinical development of the company’s portfolio of compounds through NDA submission and approval. He also is responsible for medical affairs and medical marketing support for commercialized products and leads the medical and clinical assessment of future in-licensing opportunities. Dr. Jochelson joined Somaxon from Neurocrine Biosciences, where he was VP of clinical development, responsible for the clinical development of the company’s insomnia portfolio. He graduated from the University of Witwatersrand Medical School in South Africa and subsequently received postgraduate residency training in internal medicine and anesthesiology in Canada. Dr. Stephen B. Shrewsbury MAP Pharmaceuticals Appoints VP of Clinical and Regulatory Affairs MAP Pharmaceuticals, Mountain View, Calif., a developer of novel inhaled drug products, has named Stephen B. Shrewsbury, M.D., as VP of clinical and regulatory affairs. Before joining MAP, he served as senior director of clinical development at Chiron. Dr. Shrewsbury has a diploma in pharmaceutical medicine from the Royal College of Physician’s Faculty of Pharmaceutical Medicine, a diploma of the Royal College of Obstetricians and Gynecologists, and bachelors’ degrees in medicine and surgery from Liverpool University. Dr. Marco Taglietti Stiefel Laboratories Creates Senior VP, Head of Global Research and Development Position Stiefel Laboratories, Coral Gables, Fla., an independent pharmaceutical company specializing in dermatology, has appointed Marco Taglietti, M.D., as senior VP, head of global research and development. In this newly created position, Dr. Taglietti oversees all research and development activities in Stiefel’s three R&D centers located in Oak Hill, N.Y., Maidenhead, England, and Guarulhos/Sao Paulo, Brazil. Previously, Dr. Taglietti was with Schering-Plough Research Institute, where he served as VP for worldwide clinical research in the therapeutic areas of anti-infectives, oncology, neuroscience, endocrinology, and dermatology. He holds a medical degree from the University of Pavia in Italy and trained at the university’s hospital. Drug-Delivery POOL Josette Wys Inyx Selects VP of Business Development Inyx, New York, a specialty pharmaceutical company focused on niche drug-delivery technologies and products, has appointed Josette Wys to VP of business development. In this newly created position, Ms. Wys focuses on cultivating sales, marketing, and new business relationships, with particular emphasis on increasing business at Inyx USA and the newly acquired operations in Manati, Puerto Rico. She most recently served as special project manager with the Puerto Rico Industrial Development Company. She holds a MBA from Rivier College and a B.S. in industrial engineering and operations research from Syracuse University. Device/Diagnostic POOL David Weber Stratagene Hires Leader of Global Marketing for Life-Sciences Division David Weber has been named senior VP of marketing at Stratagene, La Jolla, Calif., a developer, marketer, and manufacturer of specialized life-sciences research and diagnostic products. He leads the global marketing programs for the company’s life-sciences division. Mr. Weber brings more than 30 years of experience in life-sciences and biotechnology marketing and sales to the position. He spent 17 years at Pharmacia Biotech, Amersham Pharmacia Biotech, and Amersham Biosciences, all of which were eventually acquired by GE Healthcare. Most recently he was president, Region Americas, GE Healthcare. Mr. Weber earned a B.S. degree in biochemistry from Rutgers University. Discovery POOL Dr. Richard F. Begley Ensemble Discovery Names President and CEO Richard F. Begley, Ph.D., has been named president and CEO of Ensemble Discovery, Cambridge, Mass., an early-stage company developing a revolutionary approach to create new products in life-sciences, materials, and chemicals through its proprietary DNA Programmed Chemistry platform. Dr. Begley has joined Ensemble from 454, where he was president and CEO. He holds Ph.D. and M.S. degrees in applied physics from Stanford University and a B.S. from Fordham University. Dr. Stephen Harrison KAI Pharmaceuticals Appoints VP of Research Stephen Harrison, Ph.D., has joined KAI Pharmaceuticals as VP of research, responsible for overseeing the South San Francisco, Calif.-based company’s efforts in core technology development, drug discovery, and pre-IND activities. KAI leverages protein kinase C (PKC) signaling to build a portfolio of clinical and preclinical drug candidates for the treatment of acute cardiovascular and other important human diseases. Dr. Harrison has extensive experience in drug discovery, with an emphasis on kinases across multiple therapeutic areas. Most recently, he was VP of research at Thios Pharmaceuticals. Bryan Koontz Tripos Promotion Fills Discovery Informatics Manager Role Bryan Koontz has been promoted to senior VP and general manager of discovery informatics at Tripos. The St. Louis-based company is a provider of drug-discovery informatics products and chemistry research. Formerly VP of marketing and corporate development, Mr. Koontz now manages the discovery informatics offerings for both computational chemists and laboratory scientists and oversees the ongoing expansion of Tripos’ informatics portfolio. Mr. Koontz previously was CEO and cofounder of Optive Research, which Tripos acquired in January 2005. He completed his B.S. in mechanical engineering with a minor in engineering mechanics from The Pennsylvania State University. Mr. Koontz earned his M.S. in mechanical engineering from Massachusetts Institute of Technology. He succeeds Dr. Trevor Heritage, who has left Tripos to pursue other interests. Dr. John McKearn Kalypsys Appoints CEO Kalypsys, a privately held drug-discovery and development company based in San Diego, has promoted John McKearn, Ph.D., to CEO. Dr. McKearn joined Kalypsys in July 2003 as chief scientific officer and was promoted to president in August 2004. Previously, he was senior VP of research at Pharmacia. Over the course of his 20-year career, Dr. McKearn has authored more than 70 peer-reviewed scientific papers. He also has been issued 40 patents. He holds a bachelor’s degree from Northern Illinois University and a Ph.D. in immunology from the University of Chicago. Genomics POOL Gary C. Carter CeMines Appoints Corporate Development Executive Gary C. Carter has been named VP of corporate development at CeMines, Golden, Colo. CeMines specializes in molecular biology research and development. In this role, Mr. Carter assists with key decisions relative to market acquisition strategy, product evolutionary direction, and international merger and acquisition initiatives. Mr. Carter, 37, most recently was responsible for market research at Transgenomic. He holds a master’s degree in marketing research from the University of Georgia and a bachelor’s degree in business administration from the University of South Carolina. Emerging POOL Douglas Abel Manhattan Names CEO Following Tarpan Acquisition Douglas Abel has been named president and CEO of Manhattan Pharmaceuticals, New York, which develops proprietary prescription drugs for large, underserved patient populations. Mr. Abel, a 15-year veteran of the biotech and specialty pharmaceutical fields, most recently served as president and CEO of Tarpan Therapeutics, which Manhattan acquired in April 2005. He received his A.B. in chemistry from Lafayette College and his MBA from Temple University. Dr. Frank Armstrong CEO Appointed at Bioaccelerate Holdings Bioaccelerate Holdings, an emerging drug-development company with offices in New York and London, has promoted Frank Armstrong, M.D., to the position of CEO. Dr. Armstrong, who joined Bioaccelerate in January 2005 as chief operating officer, has replaced Lee Cole, the company’s founder, who continues to serve as chairman of the board. Before joining Bioaccelerate, Dr. Armstrong was CEO of Provensis, a wholly owned subsidiary of BTG. Dr. Christina Gamba-Vitalo David Noskowitz Robert Terifay Senior Additions Announced at Synta Synta Pharmaceuticals, an emerging product-focused biopharmaceutical company based in Lexington, Mass., has added several key executives. Christina Gamba-Vitalo, Ph.D., has been named senior director, drug safety assessment. Dr. Gamba-Vitalo joined Synta from Millennium Pharmaceuticals, where she was director of toxicology, drug safety evaluation since 2000. She was a postdoctoral fellow/associate at Yale School of Medicine’s department of pharmacology. She earned her Ph.D. and M.S. degrees from New York University and her B.S from the City College of the City University of New York. Additionally, David Noskowitz has been appointed senior director of regulatory affairs and quality assurance. Most recently, Mr. Noskowitz was at Genzyme, where he served as director of regulatory affairs. Mr. Noskowitz earned a master of engineering in chemical engineering from the University of Virginia. He also holds a B.S. in environmental engineering and a B.A. in chemistry from the University of Rochester. Robert Terifay has been appointed senior VP of commercial development and strategy. Mr. Terifay previously was at Millennium Pharmaceuticals, where he was senior VP, oncology marketing and sales and corporate commercial services. He graduated from the J.L. Kellogg Graduate School of Management at Northwestern University with a master of management degree in marketing and health service management. He also holds a B.S. in preprofessional studies (biology and chemistry) from the University of Notre Dame. Dr. Madhusudan V. Peshwa MaxCyte Appoints VP, R&D MaxCyte, a clinical-stage therapeutic company focused on nonviral cell loading technologies, has appointed Madhusudan V. Peshwa, Ph.D., as VP of research and development. Dr. Peshwa comes to Maxcyte, Gaithersburg, Md., from NewNeural, where he was executive VP of research and development. He holds a Ph.D. in chemical engineering from the University of Minnesota. Association POOL Jack Lief BIOCOM Names Board Chairman BIOCOM, the regional life-sciences industry organization for Southern California, has appointed Jack Lief as board chairman. Mr. Lief is a cofounder of Arena Pharmaceuticals and has served as president and CEO of the company since April 1997. Previously, he served as a consultant to numerous biopharmaceutical companies. In addition to his duties for San Diego-based BIOCOM, Mr. Lief serves on the board of TaiGen. Agency POOL Nancy Adams Michael Cunnion Seth Freedman Robert Goodman Jo Anne Jensen Dr. Ed Zimney Informed Medical Communications Builds Management Team Informed Medical Communications (IMC), a New York-based medical marketing network formed from the merger of The Peer Group and HealthTalk, has made management appointments. Nancy Adams, who previously served as president of The Peer Group, has been appointed executive VP of professional services at IMC. She is responsible for enhancing the professional services that IMC offers. Additionally, Ms. Adams retains responsibilities for business activities at The Peer Group. Michael Cunnion has been appointed executive VP of patient services for IMC and president of HealthTalk. He previously was executive VP of business development and marketing of HealthTalk. Seth Freedman has joined IMC as senior VP of corporate development. Most recently, Mr. Freedman was with Thomson. Robert Goodman has been named CEO of IMC. Mr. Goodman had been with HealthTalk since 2002, acting as the company’s president and CEO. Jo Anne Jensen has been named VP of market research and data analytics. Ms. Jensen has more than 19 years of experience in operational management process, productivity improvement, and market research. In other company news, Ed Zimney, M.D., has been named VP and medical director. Dr. Zimney has worked as a physician and as a branch chief for DDMAC. Additionally, he has provided regulatory counsel for multiple biotechnology and pharmaceutical companies. Jeff Backhaus Phil Deschamps Ken Moran Marcee Nelson Alex Polk Blair Price Vicki Vlastis GSW Worldwide Announces Promotions and Appointments GSW Worldwide, Columbus, Ohio, has appointed Jeff Backhaus to the role of art director for its New York office. GSW Worldwide, a subsidiary of inChord Communications, is a full-service, healthcare advertising agency. Mr. Backhaus is responsible for concept, design, presentation, execution, and production of all assigned projects. He previously served as senior art director at Concentric and holds a bachelor’s degree from the University of Wisconsin. GSW Worldwide also has promoted Phil Deschamps to president and CEO. Mr. Deschamps, who formerly served as president, oversees the agency’s continued growth and works with clients to ensure their global marketing objectives are met. He joined GSW Worldwide in 1998 as executive VP, responsible for Prozac and several other accounts for the agency. Ken Moran has joined the agency’s New York office as creative project manager. Most recently, he served as traffic director at Cline, Davis & Mann. He holds a bachelor’s degree from Hofstra University. Marcee Nelson has been appointed executive creative director of the agency’s Columbus office. Ms. Nelson was promoted to this role from her former position as senior VP/group creative director within GSW Worldwide’s women’s health practice. Before joining GSW Worldwide, she was the senior partner, deputy executive creative director, at J. Walter Thompson. She holds a bachelor’s degree from Northern Illinois University. Alex Polk has joined GSW Worldwide as editorial director, responsible for leading the New York office’s editorial department. Mr. Polk previously served as assistant director, editorial services, at Klemtner Advertising. He holds a bachelor’s degree from Rutgers College. Blair Price has joined the New York office as VP, global account director, responsible for managing one of the agency’s global pharmaceutical accounts. Mr. Price comes to GSW Worldwide from Lyons Lavey Nickel Swift, where he served as VP, account supervisor. He holds a bachelor’s degree from Boston University. Vicki Vlastis has been named account executive in GSW Worldwide’s public-relations practice, where she is the primary contact on all day-to-day account activity for the agency’s public-relations accounts. Previously, she was account executive at Lippe Taylor. She holds a bachelor’s degree from Iona College. Anna Buckley CMI Promotes Senior Supervisor, Media Strategies Communications Media (CMI), King of Prussia, Pa., has named Anna Buckley to the position of senior supervisor, media strategies. CMI is an advertising media and promotions planning company focused on the pharmaceutical industry. Ms. Buckley, who works out of the agency’s New York office, has been with the company for seven years. Andrew Chamlin Dr. Daniel Goldberg Amy West imc2 Adds Key Executives The interactive agency imc2, with offices in Dallas and New York, has made several additions to its staff. Andrew Chamlin has been named VP of the company’s pharmaceutical practice and its New York-based client-services team. Formerly director of marketing at Pfizer, Mr. Chamlin’s responsibilities include providing strategic direction and insight, and leveraging client-side product-management expertise to develop innovative, integrated marketing campaigns and concepts. Additionally, imc2 has named Daniel Goldberg, M.D., to the position of account director. Dr. Goldberg provides clients with appropriate strategic direction for communicating with physicians and consumers. Most recently Dr. Goldberg was medical account director at Bestmed, a division of the Publicis Medical Education Group. Amy West has been named senior account manager. She comes to imc2 from Roska Direct, where she directed the Shire Pharmaceuticals account. Terri L. Clevenger PR Veteran Joins WeissComm as Executive VP WeissComm Partners, San Francisco, a full-service communications agency focused on life-sciences companies, has appointed Terri L. Clevenger as executive VP. Working out of the agency’s recently opened New York office, she is responsible for the management and growth of its East Coast business. During the past 13 years, Ms. Clevenger ran her own PR and communications consulting business. Susan DiDonato CommonHealth Names Executive VP, Chief Talent Officer Susan DiDonato has been named executive VP, chief talent officer, at CommonHealth, Parsippany, N.J., a WPP Group company. Previously senior VP of human resources, Ms. DiDonato now oversees the human resources department. She began her career at CommonHealth in 1987 as an account supervisor at Ferguson, the healthcare-communications network’s founding professional advertising and promotion unit. She was later promoted to to director of account coordination at Ferguson before joining the human resources department as VP. Noel Garingan Brian Kolasinski Larry Septoff Stratagem Adds Senior-Level Professionals Stratagem Healthcare Communications, a San Francisco-based healthcare advertising agency, has added three veteran medical advertising professionals to its staff. Noel Garingan has been appointed to the role of art supervisor. He came to Stratagem from Corbett Accel Healthcare Group, where he provided art direction and brand design for marketing and promotional campaign pitches. Brian Kolasinski has been named account supervisor. An experienced pharmaceutical sales, product management, and advertising professional, he most recently served as an account supervisor at Corbett Accel. Larry Septoff has been named group copy director. During his 20 years in the industry, he has held positions at FCB Healthcare, Lyons Lavey Wolf Swift, Harrison Wilson, and Harrison Star. R. Steven Lang Stonefly Communications Hires Senior VP/Client Advisor R. Steven Lang has been named senior VP/client advisor at Stonefly Communications Group, a full-service, customer-centric communications agency based in Columbus, Ohio. In this role, Mr. Lang provides strategic marketing counsel and guidance to the brand teams of several healthcare clients, and he leads the agency teams responsible for implementing crosschannel communication campaigns. He is located at the agency’s new office in Doylestown, Pa. Mr. Lang brings 30 years of experience to Stonefly, a subsidiary of inChord Communications. Most recently, he cofounded DVC HealthCare. Erica Latte Andrea Rinkewich Tony Rodriguez Palio Communications Announces Promotions Palio Communications, Saratoga Springs, N.Y., a full-spectrum advertising and communications agency and subsidiary of inChord Communications, has made several staff promotions. Erica Latte has been promoted to account executive from account coordinator. Andrea Rinkewich has been promoted to assistant account executive from account coordinator. Tony Rodriguez has been promoted to account executive from assistant account executive. Anne M. Loomis Global Branding Specialist Joins TLM West Anne M. Loomis, a 20-year veteran of the healthcare advertising industry, has joined Torre Lazur McCann (TLM) West as executive VP and director of client services. A subsidiary of Torre Lazur McCann Healthcare Worldwide, Parsippany, N.J., TLM West is based in San Diego and offers integrated, core advertising services as well as specialty services, including television specials, digital media, and audio/video. Ms. Loomis is responsible for overall strategic development and oversees the execution of one existing and three new accounts. She comes to TLM West from Pacific Communications, where she was VP and management supervisor. She holds a bachelor’s degree from California State University in Fullerton and a MBA from the University of Southern California. Stephen Pearson Jamie Picone Compass Healthcare Communications Makes Staff Additions Compass Healthcare Communications, a full-service online marketing company based in Princeton, N.J., has announced two new hires. Stephen Pearson has joined Compass as an account manager, bringing to the agency more than 10 years of interactive marketing experience. Most recently, he worked for an online advertising firm specializing in pharmaceuticals and OTC products. He earned a B.S. from the University of Hartford. Jamie Picone has been appointed project manager. Ms. Picone has eight years of pharmaceutical industry experience across a variety of therapeutic classes, including cardiovascular, dermatology, CNS, and gastrointestinal. Most recently, she was with the marketing communications group at Novartis Pharmaceuticals. She received her B.S. from the University of Phoenix. Agnieszka Sarah Stepansky NewtonEdge Names Account Manager Agnieszka Sarah Stepansky, R.D., has joined NewtonEdge as an account manager, responsible for all aspects of client relations, including developing new accounts, managing current accounts, and overseeing project management relations. NewtonEdge, Pennington, N.J., creates strategic e-marketing and integrated learning to enhance communication. Ms. Stepansky most recently was employed by Abbott Laboratories as an anti-infective sales representative. She holds a B.S. from Cook College, Rutgers University, and a dietetic verification statement from University of Medicine and Dentistry of New Jersey. Laura Traynor Environics Communications Hires Senior Consultant Laura Traynor has joined Environics Communications as a senior consultant in the agency’s metro New York office. Environics is a full-service public relations agency. With more than 15 years of healthcare communications experience, Ms. Traynor expands the depth of Environics growing healthcare practice. Previously, she was at Accel Healthcare Communications, where she served as VP/group account supervisor. Ms. Traynor holds a bachelor’s degree in journalism from St. Bonaventure University. She is working toward her master’s degree in social policy and aging at the State University of New York. Consulting POOL Meri Bloom Ed Doherty Phil Friden Henry Piel Georgina Weber NeXus Expands Management Teams NeXus Therapeutics, a biopharmaceutical management company that employs a product development paradigm to enhance the development process of early-stage drugs and combination products, has announced the expansion of its infrastructure in key areas. Meri Bloom has been named director of regulatory affairs. She previously served as regulatory affairs manager at Cubist Pharmaceuticals. Ed Doherty has joined neXus, Framingham, Mass., as director of manufacturing. Most recently, he was director of manufacturing and process development for Nephros Therapeutics. Phil Friden has been promoted to VP, research and development, from his previous role as director. Henry Piel has been appointed director of quality assurance. He comes to neXus from Shire Biologics, where he was the compliance manager. Georgina Weber has been named associate director of clinical operations. Previously, she was senior clinical trials manager at Cato Research. CRO POOL Louis A. Angelucci III Kendle Appoints Leader for Regulatory Affairs Division Kendle, a global, full-service clinical research organization with headquarters in Cincinnati, has appointed Louis A. Angelucci III as VP of validation, for its AAC Consulting Group subsidiary in Rockville, Md. He is responsible for the day-to-day operations of the validation unit, as well as the quality and consistency of its client services. Mr. Angelucci most recently served as senior director of validation and compliance in the life-sciences division of Technip. An adjunct professor at both Temple University and the Stevens Institute of Technology, Mr. Angelucci has a M.S. degree in engineering management from Drexel University and a M.S. biomedical engineering from the University of Pennsylvania. He also holds a B.S. in biology from Ursinus College. Madeline Ducate Pharma-Olam Names VP of Global Services Madeline Ducate has been named VP of global services for Pharm-Olam International, a Houston-based multinational, contract research organization serving the pharmaceutical, biotechnology, and medical-device industries. Ms. Ducate manages all clinical activities and integrates operational issues worldwide. She brings to Pharm-Olam more than 24 years of clinical research experience, most recently as VP of global operations for Neeman Medical International. She holds a bachelor’s degree in medical technology and master’s degrees in molecular biology, management and supervising, and public health. She also is an assistant professor at the University of Medicine and Dentistry of New Jersey. Dr. Robert M. Pallay Head of Scientific and Clinical Affairs Appointed at Dimensional HealthCare Dimensional HealthCare (DHC), Cedar Knolls, N.J., which specializes in the delivery of late-phase, community-based clinical trials for the pharmaceutical and medical-device industries, has appointed Robert M. Pallay, M.D., as medical director and senior VP for scientific and clinical affairs. Dr. Palley oversees scientific and clinical operations and has responsibility for safety, protocol development, and study execution. Dr. Palley, a fellow of the American Academy of Family Physicians, brings to this position nearly 30 years of experience in clinical medicine. Previously, he served as the medical director of the Robert Wood Johnson University Medical Group’s Primary Care Center. Founder of the New Jersey Family Physicians Research Network, Dr. Pallay holds a M.D. from Northwestern University Feinberg School of Medicine. Contract-Sales POOL Larry Green Publicis Selling Solutions Announces Key Management Appointment Larry Green has joined Publicis Selling Solutions (PSS), Lawrenceville, N.J., as senior VP of business development and specialty sales. PSS, a member of the Publicis Healthcare Communications Group, provides innovative and strategic outsourced sales solutions to the pharmaceutical and biotechnology industries. Mr. Green is responsible for managing and building the company’s portfolio of services in specialty sales and emerging pharma selling solutions. He previously served as VP of sales, diabetes, at Novo Nordisk Pharmaceuticals. Media POOL Peter deTreville HMP Communications Names President and CEO Peter deTreville has rejoined HMP Communications, a privately held medical publishing and communications company based in Malvern, Pa., as president and CEO. Mr. deTreville most recently was a senior account director with Practicome Solutions, a division of Cardinal Health. Previously, he spent 15 years with HMP as VP and group publisher of the company’s cardiology division. He earned a B.A. in political science from American University and a MBA from West Chester University. Sarah Gutierrez Quadrant HealthCom Builds Staff Sarah Gutierrez has joined Quadrant HealthCom, a Chatham, N.J.-based publisher of seven medical journals and multiple educational programs, as director of new business development for The Female Patient. Ms. Gutierrez, a graduate of St. John’s University, joins Quadrant HealthCom from Cardinal Health, where she developed and sold multicultural medical-education programs. Medical-Education POOL Dr. Lisa H. Brauer Michelle Manzo Curry Rockefeller Announces Appointments Lisa H. Brauer, Ph.D., has been named scientific director for the Curry Rockefeller Group, a thought-leader focused medical-education company located in Tarrytown, N.Y. Dr. Brauer previously held faculty positions in Duke University’s department of psychiatry and behavioral science and at the University of Minnesota Medical School. Since leaving academia, she has served as a scientific consultant and writer for a number of academic, private, and nonprofit organizations. She holds a Ph.D. in biological psychology (psychopharmacology) from the University of Chicago. Michelle Manzo, MPH, has joined the company as VP, managing director, of CRG Neuroscience. Ms. Manzo has worked in the pharmaceutical industry for the past five years; most recently, she was national scientific manager and team leader, clinical and scientific affairs, at Boehringer Ingelheim Pharmaceuticals. She holds a master of public health degree from the Medical College of Virginia and a B.A. in English literature and premedical studies from Vanderbilt University. Barbara A. Fuchs Executive Director Appointed at The FCG Institute for Continuing Education Barbara A. Fuchs has been promoted to executive director of The FCG Institute for Continuing Education, North Wales, Pa., a continuing medical-education provider and subsidiary of Sudler & Hennessey. Ms. Fuchs was originally hired as continuing education coordinator at The Institute and later promoted to assistant director. Previously, she held several key clinical and administrative positions in managed care, on the hospital and the industry levels. Ms. Fuchs has bachelors’ degrees in sociology/community health and nursing and a master’s degree in health administration. Amy Marks Nancy Price Cadent Medical Communications Adds Staff Cadent Medical Communications, a medical-education and communication company based in Irving, Texas, welcomes new members to its staff. Amy Marks has joined the company as an account executive, serving as the primary contact on all day-to-day account activity with responsibility for executing the account workload. Before joining Cadent, which is a subsidiary of inChord Communications, Ms. Marks served as account manager at the Network for Medical Communication and Research. She holds a bachelor’s degree from the University of Southern Mississippi. Nancy Price has been named medical writer. Previously, Ms. Price served as associate managing editor at the Cancer Information Group. She holds a doctorate degree from the University of North Texas Health Science Center. Jack Redmond AAF-MED Appoints Executive Director, Medical and Scientific Planning Jack Redmond has joined AAF-MED, White Plains, N.Y,. as executive director, medical and scientific planning, responsible for working with clients to create and develop strategic scientific medical education and marketing for their products. AAF-MED is an independent, accredited provider of continuing medical education for physicians, nurses, and pharmacists. Mr. Redmond has more than 25 years of pharmaceutical experience. Most recently, he was with MediTech Media and International Medical Press, where he oversaw medical-education programs in diabetes, cardiology, rheumatology, women’s health, and HIV therapeutic areas. He holds bachelor’s and master’s degrees in biology from Rutgers University. Service POOL Ian Bancroft Chuck Brauer SOS Enhances Senior Management Team Science Oriented Solutions (SOS), a member of Publicis Healthcare Communications Group, has appointed Ian Bancroft as VP of Medical Science Liaison’s (MSL) global programs to lead the global expansion initiative. SOS, Kennesaw, Ga., is a full-service contract medical affairs company. Previously, Mr. Bancroft was an original member and director of G.D. Searle Global Clinical Sciences, where he spearheaded the health economics MSL department, Health Economic and Applied Therapeutics Group, and subsequently managed their merger with Pharmacia Global Medical Affairs Clinical Science Managers. He holds a B.S. from St. Andrews University in Scotland. Additionally, SOS has named Chuck Brauer director of business development, responsible for building client relationships and helping to develop novel tools and strategies for effectively communicating with clients and prospects. Mr. Brauer holds a B.A. in communications from California State University, Fullerton. Matthew Bush Jane Carter Dr. Candace Gunnarsson Rebecca Miller-Chiappinelli Jennifer Ring MetaWorks Builds Business Development Staff MetaWorks, Medford, Mass., a healthcare consulting company focused on clinical drug development and commercialization for the life-sciences industry, has announced several appointments to its business development department. Matthew Bush has been promoted to senior director of marketing and business development. He is responsible for leading the business-development team and directing corporate partnerships and referral programs. Mr. Bush has more than 10 years of experience and was one of MetaWorks’ first employees. He has a B.S. in marketing from Bentley College. Jane Carter has been appointed to the role of operations manager. Most recently, she served as project director at Perceptive Informatics, a wholly owned subsidiary of Parexel International, where she managed the development, testing, implementation, and maintenance of interactive voice response systems (IVRS), Web reports, electronic data transfers, and other technology services. She earned a B.A. in international political science from the University of Pennsylvania. Candace Gunnarsson, Ed.D., has been named director of business development. Dr. Gunnarsson previously owned and operated S2 Statistical Solutions. She also served as an adjunct statistics instructor at Union Institute and University and the University of Cincinnati. She has a B.A. in political science from San Diego State University, a M.A. in political science from Florida Atlantic University, and an Ed.D. in statistics from the University of Cincinnati. MetaWorks also has named Rebecca Miller-Chiappinelli, R.Ph., to the position of director of business development. She brings 23 years of pharmaceutical industry experience to this position, most recently as VP and account group supervisor at Torre Lazur Managed Markets. A registered pharmacist, Ms. Miller-Chiappinelli earned a B.S. from Kansas University School of Pharmacy. Jennifer Ring has been appointed marketing manager of business development. Before joining the company, she was with Chiron, where she served as pulmonary area business manager, communications manager, and project manager. Ms. Ring is a graduate of Seattle University, where she earned a B.A. in English and journalism studies. Dr. Beth Hahn MEDTAP CPR Appoints Managing Director Beth Hahn, Ph.D. has been named managing director for the MEDTAP Institute Center for Pricing and Reimbursement (CPR), a subsidiary of United BioSource. MEDTAP CPR, Arlington, Va., assists healthcare product manufacturers with strategic reimbursement research; product economic analysis; planning, design, and implementation of launch programs; and postlaunch provider support programs. Dr. Hahn’s previous experience includes 10 years with GlaxoSmithKline, most recently as director of market and business development. She holds a B.A. from the University of Iowa and a Ph.D. from the University of Illinois. Elizabeth Klaes Charlie Nucera Monitorforhire.com Builds Staff In response to increased demand for its Web-enabled resource management services, Monitorforhire.com (MFH), Conshohocken, Pa., has added staff in its San Diego office. Elizabeth Klaes has been appointed manager of clinical operations. She is responsible for managing clinical projects and maintaining relationships with existing clients. Previously, she was responsible for managing a global project team at a global CRO. Charlie Nucera has joined MFH as an account executive, responsible for managing West Coast client accounts and leading new business development in that region. Technology/Web POOL David Evans Octagon Appoints Chief Information Officer David Evans has joined Octagon Research Solutions, Wayne, Pa., as chief information officer. Octagon is a process-centric solutions provider that offers a suite of regulatory, clinical, process, and information technology solutions to the life-sciences industry. Mr. Evans is responsible for developing and implementing an enterprise information technology strategy across Octagon’s various lines of business. With more than 20 years of industry experience, he has held various executive positions, including chief technology officer and executive VP of operations at First Genetic Trust. Keith Howells Medidata Solutions Appoints VP, Engineering Keith Howells has joined Medidata Solutions, a New York-based electronic clinical data management company, as VP of engineering, responsible for the development of Medidata RAVE, the company’s electronic data capture (EDC) and electronic clinical data management (eCDM) platform. Most recently, he served as VP of Oracle’s pharmaceutical applications group. F Please send your personnel announcements to email@example.com. PharmaVOICE June 2005 Talent Pool